Keros Therapeutics (KROS) AI Stock Analysis

• Market Cap: $574.30M
• Dividend Yield: N/A
• Average Volume (3M): 1.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 91657.69%
• EPS Growth: 97.21%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): 3.62
• Shares Outstanding: 40,615,414
• 10 Day Avg. Volume: 816,801
• 30 Day Avg. Volume: 1,211,211
• PEG Ratio: -0.81
• Price to Book (P/B): 0.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.41
• Enterprise Value/Market Cap: 0.02
• Enterprise Value/Revenue: 2.83
• Enterprise Value/Gross Profit: 5.06
• Enterprise Value/Ebitda: -0.02
• 1Y Price Target: $26.43
• Price Target Upside: 88.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9

• Rating: 53 Neutral
• Price Target: $14.00 ▼( -0.28% Downside)

Keros Therapeutics is in a growth phase with strong revenue increases but significant unprofitability typical of biotech firms. The balance sheet is strong, but the company relies heavily on external financing. Technical indicators show short-term positive momentum, while valuation remains challenging due to negative earnings.

Positive Factors

Pipeline Strategy

The results suggest therapeutic potential for KER-065 in Duchenne Muscular Dystrophy and other neuromuscular diseases, which supports KROS' broader pipeline strategy.

Product Development

KER-065 is quietly becoming the company’s best internal option, showing directional gains in lean mass, reductions in fat, and improved bone density over just 85 days.

Strategic Agreements

KROS's recent agreement with TAK for elritercept in low-risk myelodysplastic syndromes, myelofibrosis, and potentially other anemia indications is viewed positively.

Negative Factors

Clinical Trials

The early termination of the TROPOS trial in PAH due to pericardial effusions across all dose cohorts was a clear setback for cibotercept.

Safety Concerns

The safety signal likely reflects on-target vascular effects, raising concerns about fluid dynamics or endothelial integrity.

Study Finalization

Many details of the Ph2 study remain to be finalized, making the addition of the program into valuation appear premature.

Keros Therapeutics Business Overview & Revenue Model

Company Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

Keros Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. As a clinical-stage company, its revenue is currently generated through partnerships with larger pharmaceutical entities, research and development collaborations, and potential upfront and milestone payments from licensing agreements. The company's long-term revenue model aims to include income from the sales of approved therapies, contingent upon successful clinical trials and regulatory approvals.

Keros Therapeutics Financial Statement Overview

Summary

Keros Therapeutics is experiencing significant revenue growth, but remains unprofitable with very high negative margins, typical of early-stage biotech firms. The balance sheet is strong with a high equity ratio and low debt, though the company requires ongoing financing due to negative cash flow from operations.

Income Statement

Keros Therapeutics has experienced significant revenue growth, with an increase from $151K in 2023 to $3.55M in 2024. However, the company remains unprofitable with a negative EBIT margin of -5937% and a net profit margin of -5277% in 2024. This highlights ongoing challenges in managing operating expenses relative to revenues, typical of early-stage biotech firms.

Balance Sheet

The company's balance sheet shows a strong equity position with an equity ratio of 92.8% and a low debt-to-equity ratio of 0.03. However, the company consistently incurs losses, which could affect its ability to sustain this financial structure long-term without additional financing.

Cash Flow

Operating cash flow is negative, indicating the company is not generating sufficient cash from its operations. The free cash flow to net income ratio is positive but reflects heavy reliance on external financing, as seen in the substantial financing cash flow in 2024. This is a common situation for biotech companies investing heavily in R&D.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.55M	151.00K	0.00	20.10M	0.00
	Gross Profit
2.32M	-664.00K	-1.61M	19.20M	-605.00K
	EBIT
-210.83M	-169.94M	-114.79M	-56.37M	-46.66M
	EBITDA
-185.82M	-152.18M	-103.06M	-56.37M	-44.92M
	Net Income Common Stockholders
-187.35M	-152.99M	-104.68M	-58.74M	-45.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
559.93M	331.15M	279.05M	230.04M	265.88M
	Total Assets
615.89M	370.02M	306.78M	255.25M	269.44M
	Total Debt
18.86M	14.44M	13.27M	1.09M	899.00K
	Net Debt
-541.07M	-316.70M	-265.78M	-228.95M	-264.98M
	Total Liabilities
44.33M	37.81M	29.36M	12.08M	7.72M
	Stockholders Equity
571.55M	332.21M	277.42M	243.17M	261.72M
Cash Flow		Free Cash Flow
-162.80M	-126.97M	-71.30M	-63.17M	-37.19M
	Operating Cash Flow
-160.87M	-124.51M	-70.06M	-62.15M	-36.89M
	Investing Cash Flow
-1.93M	-2.46M	-1.24M	-1.02M	-294.00K
	Financing Cash Flow
391.82M	178.96M	120.31M	28.55M	296.04M

Keros Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Positive. The current price of 14.04 is below the 20-day moving average (MA) of 14.08, above the 50-day MA of 12.64, and below the 200-day MA of 32.38, indicating a neutral trend. The MACD of 0.32 indicates Positive momentum. The RSI at 59.26 is Neutral, neither overbought nor oversold. The STOCH value of 74.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KROS.

Keros Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	53 Neutral	$574.30M	―	0.71%	―	91657.69%	97.21%
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
SAGE	49 Neutral	$446.49M	―	-63.53%	―	-47.94%	30.94%
TBPH	48 Neutral	$472.51M	―	-31.46%	―	6.11%	-37.79%
MGTX	44 Neutral	$442.01M	―	-216.14%	―	203.23%	-80.71%
TYRA	41 Neutral	$530.72M	―	-27.04%	―	―	6.72%
MNMD	40 Neutral	$574.20M	―	-37.07%	―	―	26.24%

Keros Therapeutics Corporate Events

Keros Therapeutics CEO to Speak at Healthcare Conference

On May 12, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025. This participation highlights Keros’ engagement with the healthcare investment community and may enhance its visibility and influence within the industry.

The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics CEO to Speak at Major Conferences

On February 28, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir Seehra, will participate in fireside chat presentations at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, and the Leerink Partners Global Healthcare Conference on March 10, 2025. These events are significant as they provide Keros with a platform to discuss its innovative therapeutic developments and engage with stakeholders, potentially impacting its industry positioning and investor relations.